Long-Acting Injectables Stocks
Specialized drug delivery developers and healthcare service providers focus on extended-release formulations and delivery systems designed to maintain therapeutic plasma concentrations over weeks or months.
As of Oct 23, 2026, Long-Acting Injectables has 10 US-listed companies worth $34.6B combined. The median member moved +2.0% over the past week; EGRX led at +13.0% and OCUL trailed at -5.4%.
Companies in Long-Acting Injectables
- ASND – Ascendis Pharma AS, $16B
- ALKS – Alkermes Plc, $7.4B
- INDV – Indivior PLC Ordinary Shares, $4.2B
- OGN – Organon & Co, $3.6B
- OCUL – Ocular Therapeutix Inc, $1.7B
- PCRX – Pacira BioSciences, Inc., $1B
- EPRX – Eupraxia Pharmaceuticals Inc. Common Stock, $493M
- EVMN – Evommune, Inc., $188M
- VANI – Vivani Medical Inc., $104M
- EGRX – Eagle Pharmaceuticals Inc, $3.3M